Phase Iii Study Of Selpercatinib Vs Chemotherapy Plus /- Pembrolizumab In Untreated Ret Positive Non-Small-Cell Lung Cancer
FUTURE ONCOLOGY(2021)
摘要
Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival.
更多查看译文
关键词
non-small-cell lung cancer, Phase III trial, RET fusion-positive, RET kinase inhibitor, RET rearrangement, selpercatinib, targeted therapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络